ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria TS ID 10250Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 May 2021
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 December 2024
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avapritinib for treating advanced systemic mastocytosis ID3770Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2022
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2011
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Canakinumab for untreated Schnitzler syndrome [ID4063]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Crovalimab for treating paroxysmal nocturnal haemoglobinuria ID6140Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 17 July 2024
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eltrombopag for treating chronic immune thrombocytopenia (TA293)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 24 July 2013
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 11 April 2024Expected publication date: 17 July 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 August 2024
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over ID6342Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) (TA845)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Midostaurin for treating advanced systemic mastocytosis (TA728)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 February 2023
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over TS ID 11956Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 27 April 2011
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2016
Ruxolitinib for treating polycythaemia vera (TA921)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 November 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Tocilizumab for treating giant cell arteritis (TA518)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 April 2018
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating giant cell arteritis TS ID 10495Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Voxelotor for treating sickle cell disease [ID1403]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 June 2024